The Role of Cholesterol and Statins in Alzheimer's Disease

Annals of Pharmacotherapy

Volumn 38, Issue 1, 2004, Pages 91-98

  Miller, Lisa J ^a   Chacko, Reni ^b  

^a South Texas Radiation Therapy Associates   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Cholesterol; Statins

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; ATHEROSCLEROSIS; CHEMISTRY; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE SEVERITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HYPERLIPIDEMIA; METABOLISM; NEUROPROTECTION; PATHOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SENILE PLAQUE;

EID: 0347623331     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D104     Document Type: Review

References (43)

1. Cummings JL, Khachaturian ZS, Definitions and diagnostic criteria. In: Gauthier S, ed. Clinical diagnosis and management of Alzheimer's disease. 2nd ed. London: Martin Dunitz, 2001:3-13.
2. Brookmeyer R, Gray S, Kawas C. Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88:1337-42.
3. De Lacoste MC, White CL 3rd. The role of cortical connectivity in Alzheimer's disease pathogenesis: a review and model system. Neurobiol Aging 1993;14:1-16.
4. Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology 1999;52:1158-65.
5. Dickson DW. Neuropathological diagnosis of Alzheimer's disease: a perspective from longitudinal clinicopathological studies. Neurobiol Aging 1997;18(4 suppl):S21-6.
6. Price DL. New perspectives on Alzheimer's disease. Annu Rev Neurosci 1986;9:489-512.
7. Raskind MA, Peskkind ER. Alzheimer's disease and related disorders. Med Clin North Am 2001;85:803-17.
8. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000;21:153-60.
9. Saunders A, Strittmatter W, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 1993;43:1467-72.
10. Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell PC, Small GW, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993;261:921-3.
11. Evans DA, Bennett DA, Wilson RS, Bienias JL, Morris MC, Scherr PA, et al. Incidence of Alzheimer disease in a biracial urban community. Arch Neurol 2003;60:185-9.
12. Castano EM, Prelli F, Wisniewski T, Golabek A, Kumar RA, Soto C, et al. Fibrillogenesis in Alzheimer's disease of amyloid B peptides and apolipoprotein E. Biochem J 1995;306:599-604.
13. Simons M, Keller P, DeStrooper B, Beyreuther K, Dotti CG, Simons K, et al. Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci USA 1998;95:6460-4.
14. Bjorkhem I, Lutjohann D, Diczfalusy U, Stahle L, Ahlborg G, Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxesterol in the circulation. J Lipid Res 1998;39:1594-600.
15. Bjorkhem I, Diczfalusy U, Lutjohann D. Removal of cholesterol from extrahepatic sources by oxidative mechanisms. Curr Opin Lipidol 1999;10:161-5.
16. Lutjohann D, Breuer O, Ahlborg G, Nennesmo I, Siden A, Diczfalusy U, et al. Cholesterol mechanism in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci 1996;93:9799-804.
17. Olesen OF, Dago L. High density lipoprotein inhibits assembly of amyloid beta peptides into fibrils. Biochem Biophys Res Commun 2000;270:62-6.
18. Lutjohann D, Papassotiropoulos A, Bjorkhem I, Locatelli S, Bagli M, Oehring RD, et al. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res 2000;41:195-8.
19. Papassotiropoulos A, Lutjohann D, Bagli M, Locatelli S, Jessen F, Rao ML, et al. Plasma 24S-hydroxy-cholesterol; a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport 2000;11:1959-62.
20. Teunissen CE, deVente J, Steinbusch HWM, DeBruijn C. Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. Neurobiol Aging 2002;23:485-508.
21. Wehr H, Parnowski T, Puzynski S, Bednarska-Makaruk M, Bisko M, Kotapka-Minc S, et al. Apolipoprotein E genotype and lipid and lipoprotein levels in dementia. Dement Geriatr Cogn Disord 2000;11:70-3.
22. Hofman A, Ott A, Breteler MM, Bots MC, Slooter AJC, Van Harskamp F, et al. Atherosclerosis, lipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997;349:151-4.
23. Jarvik GP, Wijsman EM, Kukull WA, Schellenberg GD, Yu C, Larson EB. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease: a case-control study. Neurology 1995;45:1092-6.
24. Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, et al. Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer's disease. Neuroepidemiology 1998;17:14-20.
25. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al. Apolipoprotein E ε4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002;137:149-55.
26. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995;15:1987-94.
27. McGeer EG, McGeer PL. The importance of inflammatory mechanisms in Alzheimer's disease. Exp Gerontol 1998;33:371-8.
28. Cockerill GW, Huehns TW, Weerasinghe A, Stocker C, Lerch PG, Miller NE, et al. Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selection in an in vivo model of acute inflammation. Circulation 2001;103:108-12.
29. Van Exel E, de Craen AJM, Gussekloo J, Houx P, Bootsma-Vanderweil A, MacFarlane PW, et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol 2002;51:716-21.
30. Knopp R. Drug treatment of lipid disorders. N Engl J Med 1999;341:498-511.
31. Hess D, Demchuk A, Brass L. HMGCoa reductase inhibitors (statins); a promising approach to stroke prevention. Neurology 2000;54:790-6.
32. Dahiyat M, Cumming A, Harrington C, Wischik C, Xuereb J, Corrigan F, et al. Association between Alzheimer's disease and the NOS3 gene. Ann Neurol 1999;46:664-7.
33. De la Monte SM, Lu B, Sohn Y, Etienne D, Kraft J, Ganju N, et al. Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neuorodegeneration. Neurobiol Aging 2000;21:309-19.
34. Wolozin B, Kelhnan W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000;57:1439-43.
35. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000;356:1627-31. Erratum 2001;357:562.
36. Rockwood K, Kirkland S, Hogan DB, McKnight C, Merry H, Verrault R. Use of lipid-lowering agent, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002;59:223-7.
37. Yaffe K, Barrett-Conner E, Lin F, Grady D. Serum lipoprotein levels, statin use and cognitive function in older women. Arch Neurol 2002;59:378-84.
38. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 2002;57:408-14.
39. Green RC, Jayakumar P, Benke K, Farrer L, McNagny SE, Cupples LA. Statin use is associated with reduced risk of Alzheimer's disease (abstract). Neurobiol Aging 2002;23:S273-4.
40. Locatelli S, Lutjohann D, Schmidt HHJ, Otto C, Beisiegel U, von Bergmann K. Reduction of plasma 24S-hydroxycholesterol (cerebrosterol) levels using high-dosage simvastatin in patients with hypercholesterolemia. Arch Neurol 2002;59:213-6.
41. Simons M, Schwarzler F, Lutjohann D, von Bergmann K, Beyreuther K, Dichgans J, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26 week, randomized, placebo-controlled, double blind trial. Ann Neurol 2002;52:346-50.
42. Alzheimer's Disease Lipitor treatment trial. February 2003. National Institutes of Health. www.clinicaltrials.gov/ct/action/GetStudy.htm (ac cessed 2003 Jun 25).
43. Cholesterol Lowering Agent to Slow Progression (CLASP) of Alzheimer's Disease study. May 2003. National Institutes of Health. www.clinicaltrials. gov/ct/action/GetStudy.htm (accessed 2003 May 16).